##plugins.themes.bootstrap3.article.main##

Since December 2019, the world has witnessed the Coronavirus disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2, which has been declared a pandemic by the World Health Organization in March 2020. We share our initial experience at a center in Dubai, UAE, with a diverse ethnic population and present the clinical characteristics of the first 100 laboratory-confirmed coronavirus disease patients. In this retrospective, single center study, we included all adult (≥12 years old) laboratory-confirmed COVID-19 patients who presented at Al Kuwait Hospital, Dubai, UAE between 21 February 2020 and 15 April 2020. We extracted data on the demograhics, clinical presentation, laboratory and imaging results, treatment, complications and outcomes from the electronic medical records. Results are expressed as counts and percentages for categorical variables, and mean (with range) for continuous variables. A total of one hundred patients were studied. Mean age was 44 years (range 13-82 years); 16% were aged more than 60 years. 69% were males. Most of the patients (41%) belonged to South Asia, while 33% belonged to the Middle East. 21% were diabetics, 20% were hypertensives, 10% were active smokers and 6% were known cases of asthma/chronic obstructive lung disease. Upon admission, fever (46%) and dry cough (41%) were the most common symptoms, while  24% were asymptomatic on admission. Mean duration of symptoms before hospital admission was 5.1 days (range 1-14 days). Upon admission, 8% had low platelets, 7% had lymphopenia, 61% had high C-reactive protein, 48% had high ferritin, 37% had high lactate dehydrogenase, and 31% had high D-dimers. 63% had normal chest radiography upon presentation. Computed tomography chest showed ground glass opacification in 80%, consolidation in 21% while 14% had ill defined patchy opacities. All lesions were located peripherally and 79% had bilateral involvement with predominantly lower lobe disease. 8% had critical illness. Chloroquine/hydroxychloroquine (93%) and the protease inhibitor lopinavir-ritonavir (86%) were the most commonly prescribed treatment. 8% needed non-invasive ventilation and 7% were intubated and ventilated invasively. 7% developed acute repiratory distress syndrome, 5% went into septic shock and needed vasopressor support, 2% developed acute cardiac injury, 17% had acute kidney injury, 11% had acute liver injury and 2% developed disseminated intravascular coagulation. Almost half of the patients (49%) were declared recovered after having two negative COVID-19 PCR tests while 5% died. We concluded that the Coronavirus disease 2019 (COVID-19) presents with different clinical characteristics in the UAE with an ethnic diverse background. Majority affected were young, males and diabetic. One-fourth were asymptomatic on admission, while fever and dry cough were the most common symptoms. High C-reactive protein and ferritin on admission was common. Most of the patients had normal chest radiograph on admission, while computed tomography chest showed the characteristic findings in over two-thirds. Almost half of our patients recovered while 5% died. This is an intial experience only and increased patient cohort will provide further information.

Downloads

Download data is not yet available.

References

  1. Drosten C, Günther S, Preiser W, etal . Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
    DOI  |   Google Scholar
  2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
    DOI  |   Google Scholar
  3. Zhu N, Zhang D, Wang W, etal. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
    DOI  |   Google Scholar
  4. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses 2020;12:E135.
    DOI  |   Google Scholar
  5. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Geneva: WHO; 2020.
     Google Scholar
  6. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020: WHO; 2020.
     Google Scholar
  7. The Third International Consensus Definitions for Sepsis and Septic Shock, JAMA, 2016;315(8):801-810.
    DOI  |   Google Scholar
  8. Acute Respiratory Distress Syndrome: The Berlin Definition, JAMA. 2012;307(23):2526-2533.
    DOI  |   Google Scholar
  9. Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138.
     Google Scholar
  10. Roussos. C, Koutsoukou, A. Respiratory failure. European Respiratory Journal 2003 22: 3s-14s.
    DOI  |   Google Scholar
  11. European Society of Cardiology guidance for the diagnosis and management of CV disease during the COVID-19 pandemic.
     Google Scholar
  12. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease - China, 2020. China CDC Weekly.
     Google Scholar
  13. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020[J]. China CDC Weekly, 2020, 2(8): 113-122. doi: 10.46234/ccdcw2020.032.
    DOI  |   Google Scholar
  14. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA. 2020 Apr 22. doi: 10.1001/jama.2020.6775.
    DOI  |   Google Scholar
  15. Yang J, Zheng Y, Gou X, Wang H, Wang Y, Zhou Y, Pu K et al. Prevalence of comorbidities and and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases 2020;94:91-95.
    DOI  |   Google Scholar
  16. Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-1720.
    DOI  |   Google Scholar
  17. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Segentanis T, Politou M et al. Hematological findings and complications of COVID-19. American Journal of Hematology 2020.
     Google Scholar
  18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020 Feb 15; 395(10223): 497-506.
    DOI  |   Google Scholar
  19. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7.
    DOI  |   Google Scholar
  20. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13.
    DOI  |   Google Scholar
  21. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020 Mar 13; 506: 145-148.
    DOI  |   Google Scholar
  22. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 28; 395(10229): 1054-1062
    DOI  |   Google Scholar
  23. Huang P, Liu T, Huang L, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology 2020 Feb 12.
    DOI  |   Google Scholar
  24. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019: a systematic review of imaging findings in 919 patients. American Journal of Radiology 2020;215:1-7.
    DOI  |   Google Scholar
  25. Borba MGS, Val FFA, Sampaio VS. Effect of high versus low dosages of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus-2 infection: a randomised clinical trial. JAMA 2020;3:e208857.
    DOI  |   Google Scholar
  26. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomised clinical trial. MedRxiv 2020.03.22.20040758.
    DOI  |   Google Scholar
  27. Cao B, Wang Y, Wen D. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020.
     Google Scholar
  28. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M et al. Characteristics and outcomes of 21 critically ill patients with Covid-19 in Washington state. JAMA 2020.
    DOI  |   Google Scholar